GlassScriptPhysician profile
Jamal F Ali
NPI 1528028230
$8,686.26
in general payments reported to CMS, 2019-2025
48 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,681 · 2020: $1,040 · 2021: $1,050 · 2022: $1,030 · 2023: $1,382 · 2024: $1,283 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,475 · Education: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,475.32 |
| Education | $410.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,133.58 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $868.05 | 2019-2025 | Ajovy, Austedo, Austedo Xr |
| Abbvie INC. | $501.40 | 2022-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $474.28 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Novartis Pharmaceuticals Corporation | $471.95 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $433.72 | 2019-2024 | Ultomiris, Soliris |
| Neurelis, INC. | $377.61 | 2021-2025 | Valtoco |
| Genzyme Corporation | $337.09 | 2019-2023 | |
| Pfizer INC. | $333.28 | 2019-2025 | |
| Emd Serono, INC. | $310.26 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $292.55 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Sk Life Science, INC. | $292.05 | 2023-2025 | Xcopri |
| Amgen INC. | $290.61 | 2019-2022 | |
| Eisai INC. | $277.09 | 2019-2025 | |
| Argenx US, INC. | $160.97 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $158.58 | 2020-2025 | Rexulti, Vyepti |
| Sunovion Pharmaceuticals INC. | $154.41 | 2019-2021 | |
| Tanabe Pharma America, INC. | $133.25 | 2021-2025 | Radicava |
| Kyowa Kirin, INC. | $127.28 | 2020-2024 | Nourianz |
| Tg Therapeutics, INC. | $119.55 | 2023-2025 | |
| Ucb, INC. | $114.40 | 2019-2025 | Rystiggo, Zilbrysq |
| Merz Pharmaceuticals, LLC | $111.65 | 2021-2025 | Xeomin, Inbrija |
| Allergan, INC. | $102.71 | 2019-2022 | |
| Insightec,INC | $88.20 | 2025 | Exablate |
| Acadia Pharmaceuticals INC | $84.25 | 2019-2023 | Nuplazid |
| Neurocrine Biosciences, INC. | $83.20 | 2020-2025 | Ingrezza |
| Amneal Pharmaceuticals LLC | $77.69 | 2019-2025 | Rytary, Ongentys |
| Adamas Pharmaceuticals, INC. | $76.74 | 2019 | |
| Genentech USA, INC. | $68.21 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Celgene Corporation | $62.40 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $60.26 | 2025 | Ponvory |
| Currax Pharmaceuticals LLC | $59.64 | 2022-2024 | Onzetra Xsail, Contrave |
| Otsuka America Pharmaceutical, INC. | $56.58 | 2023-2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $46.61 | 2024-2025 | Onpattro, Amvuttra |
| Ani Pharmaceuticals, INC. | $44.80 | 2024 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company LTD. | $39.84 | 2022 | |
| Sumitomo Pharma America, INC. | $34.17 | 2023-2024 | Aptiom |
| Acorda Therapeutics, INC | $33.16 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $27.07 | 2022 | |
| Nevro Corp. | $26.11 | 2024 | Senza |
| Mallinckrodt Hospital Products INC. | $25.20 | 2021 | |
| Impel Pharmaceuticals INC. | $22.65 | 2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $21.52 | 2021 | |
| Promius Pharma LLC | $17.73 | 2019 | |
| Dynasplint Systems INC. | $14.36 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.13 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.34 | 2019 | |
| Almatica Pharma LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamal Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.